Grant C Glatfelter, Allison A Clark, Natalie G Cavalco, Antonio Landavazo, John S Partilla, Marilyn Naeem, James A Golen, Andrew R Chadeayne, David R Manke, Bruce E Blough, John D McCorvy, Michael H Baumann
{"title":"Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-<i>N</i>,<i>N</i>-dimethyltryptamine Analogs in Mice.","authors":"Grant C Glatfelter, Allison A Clark, Natalie G Cavalco, Antonio Landavazo, John S Partilla, Marilyn Naeem, James A Golen, Andrew R Chadeayne, David R Manke, Bruce E Blough, John D McCorvy, Michael H Baumann","doi":"10.1021/acschemneuro.4c00513","DOIUrl":null,"url":null,"abstract":"<p><p>5-methoxy-<i>N</i>,<i>N</i>-dimethyltrytpamine (5-MeO-DMT) analogs are used as recreational drugs, but they are also being developed as potential medicines, warranting further investigation into their pharmacology. Here, we investigated the neuropharmacology of 5-MeO-DMT and several of its <i>N</i>-alkyl, <i>N</i>-allyl, and 2-methyl analogs, with three major aims: 1) to determine in vitro receptor profiles for the compounds, 2) to characterize in vitro functional activities at serotonin (5-HT) 2A receptors (5-HT<sub>2A</sub>) and 1A receptors (5-HT<sub>1A</sub>), and 3) to examine the influence of 5-HT<sub>1A</sub> on 5-HT<sub>2A</sub>-mediated psychedelic-like effects in the mouse head twitch response (HTR) model. In vitro receptor binding and functional assays showed that all 5-MeO-DMT analogs bind with high affinity and activate multiple targets (e.g., 5-HT receptor subtypes, alpha adrenergic receptors), including potent effects at 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub>. In C57Bl/6J mice, subcutaneous injection of the analogs induced HTRs with varying potencies (ED<sub>50</sub> range = 0.2-1.8 mg/kg) and maximal effects (<i>E</i><sub>max</sub> range = 20-60 HTRs/30 min), while inducing hypothermia and hypolocomotion at higher doses (ED<sub>50</sub> range = 3.2-20.6 mg/kg). 5-HT<sub>2A</sub> antagonist pretreatment blocked drug-induced HTRs, whereas 5-HT<sub>1A</sub> antagonist pretreatment enhanced HTRs. In general, <i>N</i>,<i>N</i>-dialkyl and <i>N</i>-isopropyl derivatives displayed HTR activity, while the <i>N</i>-methyl, <i>N</i>-ethyl, and 2-methyl analogs did not. Importantly, blockade of 5-HT<sub>1A</sub> unmasked latent HTR activity for the <i>N</i>-ethyl analog and markedly increased maximal responses for other HTR-active compounds (40-90 HTRs/30 min), supporting the notion that 5-HT<sub>1A</sub> agonist activity can dampen 5-HT<sub>2A</sub>-mediated HTRs. Suppression of 5-HT<sub>2A</sub>-mediated HTRs by 5-HT<sub>1A</sub> only occurred after high 5-MeO-DMT doses, suggesting involvement of other receptors in modulating psychedelic-like effects. Overall, our findings provide key information about the receptor target profiles for 5-MeO-DMT analogs, the structure-activity relationships for inducing psychedelic-like effects, and the critical role of 5-HT<sub>1A</sub> agonism in modulating acute psychoactive effects of 5-HT<sub>2A</sub> agonists.</p>","PeriodicalId":13,"journal":{"name":"ACS Chemical Neuroscience","volume":" ","pages":"4458-4477"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acschemneuro.4c00513","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
5-methoxy-N,N-dimethyltrytpamine (5-MeO-DMT) analogs are used as recreational drugs, but they are also being developed as potential medicines, warranting further investigation into their pharmacology. Here, we investigated the neuropharmacology of 5-MeO-DMT and several of its N-alkyl, N-allyl, and 2-methyl analogs, with three major aims: 1) to determine in vitro receptor profiles for the compounds, 2) to characterize in vitro functional activities at serotonin (5-HT) 2A receptors (5-HT2A) and 1A receptors (5-HT1A), and 3) to examine the influence of 5-HT1A on 5-HT2A-mediated psychedelic-like effects in the mouse head twitch response (HTR) model. In vitro receptor binding and functional assays showed that all 5-MeO-DMT analogs bind with high affinity and activate multiple targets (e.g., 5-HT receptor subtypes, alpha adrenergic receptors), including potent effects at 5-HT2A and 5-HT1A. In C57Bl/6J mice, subcutaneous injection of the analogs induced HTRs with varying potencies (ED50 range = 0.2-1.8 mg/kg) and maximal effects (Emax range = 20-60 HTRs/30 min), while inducing hypothermia and hypolocomotion at higher doses (ED50 range = 3.2-20.6 mg/kg). 5-HT2A antagonist pretreatment blocked drug-induced HTRs, whereas 5-HT1A antagonist pretreatment enhanced HTRs. In general, N,N-dialkyl and N-isopropyl derivatives displayed HTR activity, while the N-methyl, N-ethyl, and 2-methyl analogs did not. Importantly, blockade of 5-HT1A unmasked latent HTR activity for the N-ethyl analog and markedly increased maximal responses for other HTR-active compounds (40-90 HTRs/30 min), supporting the notion that 5-HT1A agonist activity can dampen 5-HT2A-mediated HTRs. Suppression of 5-HT2A-mediated HTRs by 5-HT1A only occurred after high 5-MeO-DMT doses, suggesting involvement of other receptors in modulating psychedelic-like effects. Overall, our findings provide key information about the receptor target profiles for 5-MeO-DMT analogs, the structure-activity relationships for inducing psychedelic-like effects, and the critical role of 5-HT1A agonism in modulating acute psychoactive effects of 5-HT2A agonists.
期刊介绍:
ACS Chemical Neuroscience publishes high-quality research articles and reviews that showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders. Research in the journal focuses on aspects of chemical neurobiology and bio-neurochemistry such as the following:
Neurotransmitters and receptors
Neuropharmaceuticals and therapeutics
Neural development—Plasticity, and degeneration
Chemical, physical, and computational methods in neuroscience
Neuronal diseases—basis, detection, and treatment
Mechanism of aging, learning, memory and behavior
Pain and sensory processing
Neurotoxins
Neuroscience-inspired bioengineering
Development of methods in chemical neurobiology
Neuroimaging agents and technologies
Animal models for central nervous system diseases
Behavioral research